Halozyme Therapeutics | HALO - Net Income

Stock Price
80.67
Daily Change
2.25 2.87%
Monthly
7.40%
Yearly
41.28%
Q1 Forecast
69.50

Halozyme Therapeutics reported $175.22M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amarin USD -7.74M 6.4M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Baxter International USD -46M 137M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Halozyme Therapeutics USD 175.22M 10.06M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
MannKind USD 668K 12.49M Jun/2025
Pfizer USD -1.65B 5.19B Dec/2025
United Therapeutics USD 338.7M 29.2M Sep/2025